Trials / Completed
CompletedNCT05765955
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, PK and the Immunosuppressive Effects of p38 MAPK Inhibitor POLB 001 on the Intradermal and Intravenous LPS Challenge Response in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Poolbeg Pharma plc · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POLB 001 | Investigational Medicinal Product |
| DRUG | Placebo | Matching Placebo |
Timeline
- Start date
- 2022-07-22
- Primary completion
- 2022-12-14
- Completion
- 2022-12-16
- First posted
- 2023-03-13
- Last updated
- 2023-03-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05765955. Inclusion in this directory is not an endorsement.